Cubist will boost antibiotics lineup with Optimer and Trius buys

07/31/2013 | Reuters · Bloomberg Businessweek

Cubist Pharmaceuticals plans to acquire antibiotics-makers Optimer Pharmaceuticals for $801 million and Trius Therapeutics for $818 million contingent on certain milestones in a bid to increase its product pipeline. The deal grants Cubist access to Optimer's recently approved drug Dificid for Clostridium difficile-associated diarrhea and Trius' late-stage antibiotic tedizolid phosphate.

View Full Article in:

Reuters · Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX